Genetic engineering of pollen allergens for hayfever immunotherapy

Expert Review of Vaccines

Volumn 2, Issue 1, 2003, Pages 75-84

  Bhalla, Prem L ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Genetic engineering; Hayfever; Hypoallergen; IgE; Immunotherapy; Pollen allergy; Recombinant allergen; Type I allergy

Indexed keywords

ANTIHISTAMINIC AGENT; CORTICOSTEROID; CYANIC ACID DERIVATIVE; FORMALDEHYDE; GLUTARALDEHYDE; IMMUNOGLOBULIN E; OLIGOMER; POLLEN ANTIGEN; POTASSIUM DERIVATIVE; RECOMBINANT PROTEIN;

ALLERGIC ASTHMA; ALLERGIC DISEASE; ALLERGIC RHINITIS; CHEMICAL MODIFICATION; CLINICAL TRIAL; CONFORMATION; DRUG EFFICACY; DRUG IDENTIFICATION; DRUG SAFETY; DRUG SYNTHESIS; ENVIRONMENTAL FACTOR; GENE DELETION; GENE SEQUENCE; GENETIC ENGINEERING; GRASS POLLEN; HAY FEVER; HUMAN; HYBRID; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOTHERAPY; MOLECULAR BIOLOGY; MOLECULAR CLONING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RHINOCONJUNCTIVITIS; SITE DIRECTED MUTAGENESIS; TH2 CELL; TREATMENT OUTCOME; WORLD HEALTH ORGANIZATION;

ADMINISTRATION, ORAL; ALLERGENS; ANAPHYLAXIS; DESENSITIZATION, IMMUNOLOGIC; EPITOPES; HUMANS; HYPERSENSITIVITY, IMMEDIATE; IMMUNOGLOBULIN E; IMMUNOLOGIC MEMORY; LYMPHOCYTE SUBSETS; MUTAGENESIS, SITE-DIRECTED; PLANT PROTEINS; POLLEN; PROTEIN CONFORMATION; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; RHINITIS, ALLERGIC, SEASONAL; SAFETY; SEQUENCE DELETION; VACCINES, DNA;

EID: 0038668868     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.2.1.75     Document Type: Review

References (69)

1. Miyamoto T. Advances in Allergology and Clinical Immunology. Godard P, Bousquet, J, Michel FB (Eds). The Parthenon Publishing Group, Cornforth, UK (1992).
2. Burney P, Bousquet J, Blumenthal M et al. Evidence for an increase in atopic disease and possible cause. Clin. Exp. Allergy 23, 484-492 (1993).
3. Valenta R. The future of antigen-specific immunotherapy of allergy. Nat. Rev. Immunol. 2, 446-453 (2002). Excellent overview of allergy immunotherapy strategies.
4. Noon L. Prophylactic inoculation for hay fever. Lancet 1, 1572-1573 (1911).
5. Varney VA, Gaga M, Frew AJ, Aber VR, Kay AB, Durham SR. Usefulness of immunotherapy in patients with severe summer hay fever uncontrolled by antiallergenic drugs. Br. Med J. 302, 265-269 (1991).
6. Grammer LC, Shaughnessy MA, Paterson R. Modified forms of allergen immunotherapy. J. Allergy Clin. Immunol. 76, 397-401 (1985).
7. Bousquet J, Lockey R, Malling H J et al. Allergen Immunotherapy: Therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102, 558-562 (1998). Clinical practice immunotherapy recommendation paper.
8. Durham SR, Till SJ. Immunologic changes associated with allergen immunotherapy. J. Allergy Clin. Immunol. 102, 157-164, (1998).
9. Ebner C, Siemann U, Bohle B et al. Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clone specific for Phl p 1, a major grass pollen allergen. Clin. Exp. Allergy 27, 1007-1015 (1997).
10. Ball T, Sperr WR, Valent P et al. Induction of antibody responses to new B-cell epitopes indicates vaccination character of allergen immunotherapy. Eur. J. Immunol. 29, 2026-2036 (1999).
11. Kay AB. Allergy and Allergic diseases. N. Engl. J. Med 344, 30-37 (2001). Reviews underlying mechanisms of allergy.
12. Platts-Mills TAE, Mueller GA, Wheatley LM. Future directions for allergen immunotherapy. J. Allergy Clin. Immunol. 102, 335-343 (1998).
13. Durham SR, Varney VA, Gaga M et al. Grass pollen immunotherapy decreases the number of mast cells in the skin. Clin. Exp. Allergy 29, 1490-1496 (1999).
14. Abramson M, Puy R, Weiner J. Immunotherapy in asthma: an updated systematic review. Allergy 54, 1022-1041 (1999).
15. Robinson DS. Th-2 cytokines in allergic disease. Br. Med Bull 56(4), 956-968 (2000).
16. Focke M et al. Nonanaphylactic synthetic peptides derived from B-cell epitotopes of the major grass-pollen allergen, Phl p 1, for allergy vaccination FASEB J. 15, 2045-2047 (2001).
17. van Neerven RJ, Wikborg T, Lund G et al. Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T-cells by inhibiting serum-IgEfacilitated allergen presentation. J. Immunol. 163, 2944-2955 (1999).
18. Fziedhoff LP., Ehrlich-Kautzky E et al. A study of human immune response to Lolium perenne (rye) pollen and its components, Lol p 1 and Lol p 2 (rye I and rye II). Allergy Clin Immunol. 78, 1190-1201 (1986).
19. de Weerd, Bhalla PL, Singh MB. Aeroallergens and polliniosis: Molecular and immunological characteristics of cloned pollen allergens. Aerobiologia (In Press) (2002).
20. Griffith IJ, Smith PM, Pollock J et al. Cloning and sequencing of Lol p 1, the major allergenic protein of rye-grass pollen. FEBS Lett. 279, 210-215 (1991).
21. Singh MB, Hough T, Theerakulpisut P et al. Isolation of CDNA encoding a newly identified major allergenic protein of ryegrass pollen: Intracellular targeting to the amloplast. Proc. Natl Acad. Sci. USA 88, 1384-1388 (1991).
22. Ong EK, Singh MB, Knox RB Seasonal distribution of pollen in the atmosphere of Melbourne: an airborne pollen calendar. Aerobiologia 11, 219-229 (1995).
23. Suphioglu C, Singh MB, Taylor P et al. Mechanism of grass-pollen-induced asthma. Lancet 339, 569-572 (1992).
24. Ong EK, Griffith IJ, Knox RB, Singh MB. Cloning of a CDNA encoding a group-V (group IX) allergen isoform from rye-grass pollen that demonstrates a specific antigenic immunoreactivity. Gene 134, 235-240 (1993).
25. Bhalla PL, Swoboda I, Singh MB. Antisense mediated silencing of a gene encoding a major ryegrass pollen allergen. Proc. Natl Acad. Sci. USA 96, 11676-11680 (1999).
26. Hirschwehr R, Heppner C, Spitzauer S et al. Identification of common allergenic structures in mugwort and ragweed pollen. J. Allergy Clin. Immunol. 101, 196-206 (1998).
27. Himly M, Jahn-Schmid B, Dedic A et al. Art v 1, the major allergen of mugwort pollen, is a modular glycoprotein with a defensin-like and a hydroxyproline-rich domain. FASEB J. express article 10.1096/fj.02-0472fje Published online November 15 (2002).
28. Valenta R, Vrtala S, Laffer S, Spitzauer S, Kraft D. Recombinant allergens. Allergy 53, 552-561 (1998).
29. Valenta R, Lidholm J, Niederberger V, Hayek B, Kraft D, Gronlund H. The recombinant allergen-based concept of component resolved diagonsis and immunotherapy (CRD and CRIT). Clin. Exp. Allergy 29, 896-904 (1999).
30. Grammer LC, Shaughnessy MA, Paterson R. Modified forms of allergen immunotherapy. J. Allergy Clin. Immunol. 76, 397-401 (1985).
31. Hayglass KT, Stefura WP. Anti-IFN gamma treatment blocks the ability of polymerized allergens to inhibit specific IgE responses. J. Exp. Med. 173, 279-287 (1991).
32. Norman PS, Lichtenstein LM, Marsh DG. Studies on allergoids from naturally occuring allergens. IV. Efficacy and safety of long-term allergoid treatment of ragweed hay fever. J. Allergy Clin Immunol. 68, 460-470 (1981).
33. Mohapatra S, Cao Y, Ni H, Salo D. In pursuit of the 'holy grail': recombinant allergens and peptides as catalysts for the allergen specific immunotherapy. Allergy 50(Suppl. 25), 37-44 (1995).
34. Griffith IJ, Pollock J, Klapper DG, Rogers BL, Nault AK. Sequence polymorphism of Amb a 1 and Amb a 2, the major allergens of Ambrosia artemisifolia (short ragweed). Int. Arch. Allergy Appl. Immunol. 96, 296-304 (1991).
35. Rafner T, Griffith IJ, Kuo MC, Bond JF, Rogers BL, Klapper DG, Cloning of Amb a 1 (Antigen E), the major allergen family of short ragweed pollen. J. Biol. Chem. 266, 1229-1236 (1991).
36. Breiteneder H, Pettenburger K, Bito A et al. The gene coding for the major birch allergen, Bet v 1, is highly homologous to a pea disease resistance response gene. EMBO J. 8, 1935-1938 (1989).
37. Ferreira F, Hirtenlehner K, Jilek A et al. Dissection of immunoglobulin E and T-lymphocyte reactivity of isoforms of the major birch pollen allergen Bet v 1. Potential use of hypoallergenic isoforms for immunotherapy. J. Exp. Med. 183, 599-609 (1996). Use of naturally occurring isoforms for immunotherapy.
38. Kraft D, Ferreira F, Ebner C et al. Recombinant allergens: the future of the diagnosis and treatment of atopic allergy. Allergy 53, 62-66 (1998).
39. Ferreira F, Ebner C, Kramer B et al. Modulation of IgE reactivity of allergens by site-directed mutagenesis: potential use of hypoallergenic variants for immunotherapy. FASEB J. 12, 231-242 (1998).
40. Esch RE, Klapper DG. Isolation and characterisation of a major cross-reactive grass group-1 antigenic determinant. Mol. Immunol. 26, 557-561 (1989).
41. Tamborini E, Faccini S, Lindholm J et al Biochemical and immunological characterization of recombinant allergen Lol p 1. Eur. J. Biochem 249, 886-894 (1997).
42. Schramm G, Kahlert H, Suck R et al. 'Allergen engineering': variants of the timothy grass pollen allergen Phl p 5 with reduced IgE-binding capacity but conserved T-cell reactivity. J. Immunol. 162, 2406-2414 (1999).
43. Swoboda I, de Weerd N, Bhalla PL et al. Mutants of the major ryegrass pollen allergen, Lol p 5, with reduced IgE-binding capacity: candidates for grass pollen-specific immunotherapy. Eur. J. Immunol. 32, 270-280 (2002). Construction of rye grass vaccine candidates.
44. Ong EK, Knox RB, Singh MB. Mapping of the antigenic epitopes of Lol p VB using gene fragmentation. Mol. Immunol. 32, 295-302 (1995).
45. Suphioglu C, Blaher B, Rolland JM etal. B. Molecular basis of IgE-recognition of Lol p 5, a major allergen of ryegrass pollen. Mol. Immunol. 35, 293-305 (1998).
46. Blaher B, Suphioglu C, Knox RB, Singh MB, McCluskey J, Rolland JM. Identification of T-cell epitopes of Lol p 9, a major allergen of ryegrass (Lolium perenne) pollen. J. Allergy Clin. Immunol. 98, 124-132 (1996).
47. Suphioglu C, Ferreira F, Knox RB. Molecular cloning and immunological characterisation of Cyn d 7, a novel calcium-binding allergen from Bermuda grass pollen. FEBS Lett 402, 167-172 (1997).
48. Smith PM, Xu H, Swoboda I, Singh MB Identification of a Ca2+ binding protein as a new Bermuda grass pollen allergen Cyn d 7. IgE cross-reactivity with oilseed rape pollen allergen Bra r 1. Int. Arch. Allergy Immunol. 114, 265-271 (1997).
49. Engel E, Richter K, Obermeyer G et al. Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J. Biol. Chem. 272, 28630-28637 (1997).
50. Twardosz A, Hayek B, Seiberler S et al. Molecular characterisation, expression in Escherichia coli and epitope anaylsis of a two EF-hand calcium-binding birch pollen allergen, Bet v 4. Biochem. Biophys. Res. Commun. 239, 197-204 (1997).
51. Okada T, Swoboda I, Bhalla PL, Toriyama K, Singh MB. Engineering of hypoallergenic mutants of the Brassica pollen allergen, Bra r 1, for immunotherapy. FEBS Lett. 434, 255-260 (1998).
52. Valenta R, Hayek B, Seiberler S et al. Calcium-binding allergens: From plants to man. Int. Arch. Allergy Immunol. 117, 160-166 (1998).
53. Scheiner O, Kraft D. Basic and practical aspects of recombinant allergens. Allergy 50, 384-391 (1995).
54. de Weerd N, Bhalla PL Singh MB. Effect of cysteine mutagenesis on human IgE reactivity to a recombinant form of the major rye grass pollen allergen Lol p 1. Allergolgy Int. (In Press).
55. Petersen A, Schramm G, Schlaak M, Becker WM. Post-translational modifications influence IgE reactivity to the major allergen Phl p 1 of timothy grass pollen. Clin. Exptl. Allergy 28, 315-321 (1998).
56. Visco V, Dolecek C, Denepoux S et al. Human monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J. Immunol. 157, 956-962 (1996).
57. Laffer S, Vangelista L, Steinberger P, Kraft D, Pastore A, Valenta P, Molecular characterisation of Bip 1, a monoclonal anibody that modulates IgE binding to birch pollen allergen Bet v 1. J. Immunol. 157, 4953-4962 (1996).
58. Vrtala S, Hirtenlehner K, Vangelista L et al. Conversion of the major birch pollen allergen, Bet v 1, into two nonanaphylactic T-cell epitope-containing fragments: Candidates for a novel form of specific immunotherapy. J. Clin. Invest. 99, 1673-1681 (1997).
59. Vrtala S, Hirtenlehner K, Susani M et al. Genetic engineering of a hypoallergenic trimer of the major birch pollen allergen, Bet v 1. The FASEB Journal express article 10.1096/fj.00-0767fje. Published online July 24, 2001. Hypoallergenic forms of tree allergen.
60. Linhart B, Jahn-Schmid B, Verdino P, Keller W, Ebner C, Kraft D, Valenta R. Combination vaccines for the treatment of grass pollen allergy consisting of genetically engineered hybrid molecules with increased immunogenicity FASEB Journal express article 10.1096/fj.00-1012fje. Published online June 21, 2001.
61. Tang Dc, DeVit M, Johnston SA. Genetic immunization is a simple method to eliciting an immune response. Nature 92, 152-154 (1992).
62. Johnston SA, Talaat AM, McGuire MJ. Genetic immunization: What's in a name? Arch. Med. Res. 33, 325-329 (2002). Reviews limitations and improvement approaches of gene vaccine.
63. Tighe H, Corr M, Roman M, Raz E. Gene vaccination: plasmid DNA is more than just a blueprint. Immunol. Today 19, 89-97 (1998).
64. Hartl A, Kiesslich J, Weiss R etal. Immune responses after immunization with plasmid DNA encoding Bet v 1, the major allergen of birch pollen. J. Allergy Clin. Immunol. 103, 107-113 (1999).
65. Bjorksten B, Moller C, Broberger U et al. Clinical and immunological effects of oral immunotherapy with a standardized birch pollen extract. Allergy 41, 90-95 (1986).
66. Moller C, Dreborg S, Lanner A, Bjorksten B. Oral immunotherapy of children with rhinoconjunctivitis due to birch pollen allergy. A double-blind study. Allergy 41, 271-279 (1986).
67. Litwin A, Flanagan M, Entis G et al. Oral immunotherapy with short ragweed extract in a novel encapsulated preparation: a double-blind study. J. Allergy Clin. Immunol. 100, 30-38 (1997).
68. de Weerd N, Bhalla PL, Singh MB. Oral immunization with a recombinant major grass pollen allergen induces blocking antibodies in mice. Int. Arch. Allergy Immunol. (In Press) (2002).
69. Hiller R, Laffer S, Harwanegg C, Huber M, Schmidt WM et al. Microarrayed allergen molecules: diagnostic gatekeepers for allergy treatment. The FASEB Journal express article 10.1096/fj.01-0711fje. Published online January 14, 2002. Demonstration of microarray in allergy diagnosis.